A camel milk formula powder for assisting in regulating blood lipids and a preparation process thereof

Abstract

This invention discloses a camel milk formula powder for assisting in the regulation of blood lipids and its preparation process, belonging to the field of functional dairy product deep processing technology. This formula powder constructs a five-in-one synergistic lipid-regulating network of "exogenous absorption inhibition, endogenous synthesis regulation, oxidative stress protection, intestinal microecological regulation, and vascular endothelial protection." Its core components include a specific ratio of compounded phytosterol esters, microencapsulated complex oils, and medicinal and edible extracts. The preparation process employs stepwise low-temperature microencapsulation and cold spray agglomeration granulation technology to achieve full-process low-temperature protection of active ingredients, with lactoferrin retention ≥90% and ω-3 fatty acid bioavailability increased by more than 25%. This invention's product has comprehensive lipid-regulating effects, 3 times improved oxidative stability, and produces no oil residue or off-odor when mixed, making it suitable for long-term consumption by people with borderline elevated blood lipids. It can also achieve continuous industrial production with a batch mixing uniformity RSD ≤2%.

Description

Technical Field

[0001] This invention relates to the field of functional dairy product deep processing technology, specifically to a formulated camel milk powder that achieves auxiliary regulation of blood lipids through a multi-pathway synergistic mechanism and employs stepwise low-temperature microencapsulation and cold spray agglomeration granulation technology to maximize the retention of the functional potency of active ingredients. This product is suitable for individuals with borderline elevated blood lipids, those with metabolic syndrome, and middle-aged and elderly individuals requiring daily blood lipid management. Its preparation process enables efficient encapsulation of heat-sensitive active ingredients, improves the physicochemical stability of the system, and allows for continuous industrial production. It belongs to the interdisciplinary innovation field of dairy-based functional food formulation design and advanced drying and processing technology. Background Technology

[0002] With the improvement of national living standards and changes in dietary structure, the overall prevalence of dyslipidemia among adults in my country has reached 40.4%, and it is showing an upward trend and a younger age of onset. Hyperlipidemia is an independent risk factor for atherosclerotic cardiovascular disease and is also closely related to chronic metabolic diseases such as fatty liver and type 2 diabetes. Although statins and fibrates, which are commonly used in clinical practice, have definite lipid-lowering effects, long-term use can lead to adverse reactions such as liver and kidney damage and muscle toxicity, resulting in poor patient compliance.

[0003] Dietary intervention, due to its mildness and safety, has become an important direction for lipid management. Functional milk powder is an ideal nutrient carrier, among which camel milk, rich in unsaturated fatty acids, insulin-like proteins, lactoferrin and other active ingredients, has attracted much attention for its lipid-regulating effect by inhibiting HMG-CoA reductase activity and upregulating LDL receptor expression.

[0004] However, existing camel milk lipid-regulating products still face three major bottlenecks: First, the concentration of lipid-lowering active substances in camel milk is low, making it difficult to achieve effective dosage through simple consumption; second, the lipid-regulating pathway is singular, mostly relying on phytosterol esters to inhibit intestinal cholesterol absorption, without forming a multi-target synergistic network; and third, the active ingredients have poor stability, with ω-3 polyunsaturated fatty acids easily oxidized and rancid, phytosterol esters exhibiting poor water dispersibility, and traditional high-temperature spray drying processes damaging heat-sensitive proteins in camel milk, leading to reduced product efficacy and deteriorated sensory quality. Therefore, developing camel milk formula powder that synergistically regulates lipids through multiple pathways while efficiently preserving active ingredients is of significant practical importance. Summary of the Invention

[0005] The purpose of this invention is to overcome the aforementioned shortcomings of existing technologies and provide a camel milk formula powder for assisting in the regulation of blood lipids. Through the scientific compounding of specific components, it forms a synergistic lipid-regulating network from five dimensions: inhibition of exogenous absorption, regulation of endogenous synthesis, protection against oxidative stress, regulation of intestinal microecology, and protection of vascular endothelium. Simultaneously, this invention also provides a preparation process for this formula powder. This process innovatively employs "stepwise low-temperature microencapsulation and cold spray agglomeration granulation" technology, which, while ensuring uniform mixing of all components, maximizes the protection of the activity and stability of polyunsaturated fatty acids, phytosterol esters, and endogenous heat-sensitive proteins in camel milk, endowing the product with excellent sensory qualities and superior storage stability.

[0006] The specific objectives of this invention include:

[0007] 1. Construct a five-in-one formula system of "basic nutritional support + core lipid regulation + vascular protection + intestinal regulation + antioxidant protection" to achieve systemic blood lipid regulation through multiple targets and pathways, while taking into account the nutritional comprehensiveness and gastrointestinal tolerance of the product.

[0008] 2. Optimize the microcapsule wall material system to enhance its resistance to gastric acid and intestinal targeted release, thereby increasing the bioavailability of ω-3 fatty acids and phytosterol esters by more than 25%.

[0009] 3. Improve the preparation process to solve the problem of uneven distribution of functional components caused by dry mixing process, realize continuous industrial production, and achieve batch mixing uniformity RSD≤2%.

[0010] 4. Establish a fully controlled low-temperature process chain to ensure that the retention rate of heat-sensitive active proteins such as lactoferrin and immunoglobulins in camel milk is ≥90%, and the peroxide value of the product after 6 months of accelerated storage is ≤5 meq / kg.

[0011] 5. Provide a complete chain of scientific evidence, including molecular mechanism verification, animal experiments, and human clinical trial data, to fully demonstrate the safety and effectiveness of the product.

[0012] To achieve the above objectives, the present invention adopts the following technical solution:

[0013] (a) A camel milk formula powder for assisting in the regulation of blood lipids

[0014] This formula powder is based on the concept of systems biology and has been carefully constructed into a multi-level, multi-target complex lipid-regulating matrix. The specific components it contains and the mass fraction of each component in every 100 parts by weight of the finished product are as follows:

[0015] Skimmed camel milk powder: 45-50 parts; Demineralized whey powder: 5-8 parts; Phytosterol esters: 3-4 parts (β-sitosterol ester: campesterol ester = 7:3); Microencapsulated complex oil powder: 7-9 parts; Resistant dextrin: 10-12 parts; Galacto-oligosaccharides: 2-3 parts; Erythritol: 5-7 parts; Maltitol: 3-5 parts; Mixed natural tocopherols: 0.1-0.15 parts; Rosemary extract: 0.03-0.05 parts; Soy lecithin: 0.4-0.6 parts; Milk phospholipids: 0.1-0.2 parts; Hawthorn extract (total flavonoids ≥20%): 1.5-2.5 parts; Pueraria lobata extract (puerarin ≥15%): 1-2 parts; Calcium carbonate: 1-1.5 parts; Vitamin D3: 0.0001-0.0002 parts.

[0016] Furthermore, the defatted camel milk powder has a protein content of ≥34%, a fat content of ≤1.5%, a moisture content of ≤3.0%, an ash content of ≤7.5%, and a lactose content of ≤48%. It is the backbone that carries all functional factors and provides the original active proteins of camel milk. The defatting process removes most of the saturated fat, making it more suitable for blood lipid management needs.

[0017] Furthermore, the phytosterol ester is a compound of β-sitosterol ester and campesterol ester in a 7:3 mass ratio, with an esterification degree ≥98% and a melting point of 45-55℃. This ratio of sterol ester increases bioavailability by 15% compared to β-sitosterol ester alone, and the amount added is controlled within the FDA-recommended daily intake range (≤3g / day) to avoid excessive intake leading to impaired absorption of fat-soluble vitamins.

[0018] Furthermore, the microencapsulated composite oil powder is a highly complex encapsulation system, with its core oil being a blend of linseed oil, Schizochytrium oil, and peony seed oil in a weight ratio of 4:1:0.5. This formulation is designed to optimize the ratio of ω-3 to ω-6 fatty acids to 5:1, meeting the human body's requirements for healthy fatty acids. α-Linolenic acid can be partially converted into EPA in the body, synergistically working with directly provided DHA to promote fatty acid β-oxidation and reduce the assembly and secretion of very low-density lipoprotein (VLDL) in the liver by activating peroxisome proliferator-activated receptor α (PPAR-α); paeonol in peony seed oil enhances antioxidant and vascular endothelial protective effects.

[0019] For the microcapsule wall material of this oil powder, the present invention designs a multilayer composite wall material system, which contains the following components and their proportions in every 100 parts by weight of the powder: sodium octenyl succinate starch: 2-4 parts;

[0020] Sodium caseinate: 1-2 parts; Tea polyphenols: 0.06-0.1 parts; Chitosan: 0.1-0.3 parts; Isomaltooligosaccharide: 10-18 parts; The design of this composite wall material is ingenious. Sodium octenyl succinate starch, due to its unique amphiphilicity, can form a robust interfacial film on the surface of oil droplets, providing excellent emulsification and shear resistance. Sodium caseinate has both emulsifying and film-forming properties; its molecules unfold and cross-link at the oil-water interface, forming a protein film with good oxygen barrier properties. The phenolic hydroxyl groups of tea polyphenols combine with the amino groups of casein through hydrogen bonds, forming a dense antioxidant network at the interface, which can actively quench free radicals and break the oxidation chain reaction at its source. Chitosan forms a gel protective layer in gastric acid, allowing the microcapsules to release their contents only in the intestinal pH environment, achieving targeted release. Isomaltooligosaccharide, as a filler and drying matrix, ensures the good physical state of the powder due to its low sweetness and low hygroscopicity.

[0021] Furthermore, the resistant dextrin is a low-viscosity, highly soluble water-soluble dietary fiber with an average degree of polymerization preferably of 8-15. It performs three functions in the formulation: as a prebiotic, it selectively promotes the proliferation of beneficial bacteria such as Bifidobacteria and Lactobacillus in the gut, positively regulating host cholesterol and bile acid metabolism through the gut-liver axis; its high water-holding capacity and viscosity can form a physical barrier in the intestine, slowing down the absorption rate of carbohydrates and lipids, and suppressing the rapid rise in postprandial blood glucose and triglycerides; as a processing aid, it can encapsulate powder particles during subsequent granulation, improving powder flowability and dispersibility.

[0022] Furthermore, the galactooligosaccharide is a natural prebiotic with better prebiotic effects than resistant dextrin and better gastrointestinal tolerance. It works synergistically with resistant dextrin to regulate the intestinal flora and further enhance the lipid-regulating effect.

[0023] Furthermore, erythritol and maltitol are blended in a 2:1 mass ratio as a sweetener. Erythritol is a zero-calorie, high-tolerance natural sweetener with a glycemic index close to zero; maltitol improves the product's taste and masks the slight fishy smell of algal oil. The blended sweetener reduces the risk of gastrointestinal irritation associated with erythritol alone, making it suitable for all types of people.

[0024] Furthermore, the mixed natural tocopherols are a mixture of natural α-, β-, γ-, and δ-tocopherols extracted from soybean oil deodorized distillate. They work synergistically with rosemary extract (sarsaparilla acid) for antioxidant effects, which is twice as effective as using tocopherols alone. At the same time, the amount of tocopherol added is reduced to avoid abnormal coagulation function caused by excessive amounts.

[0025] Furthermore, the soybean lecithin and milk lecithin are compounded at a mass ratio of 4:1 as emulsifiers. Milk lecithin has a better emulsifying effect than soybean lecithin and is more compatible with camel milk matrix, reducing the total amount of phospholipids added and avoiding the product from having a beany taste.

[0026] Furthermore, the hawthorn extract is rich in flavonoids such as hyperoside, quercetin, and proanthocyanidins, while the kudzu root extract is mainly composed of puerarin and daidzein. The combination of these two ingredients can synergistically enhance the liver's lipid clearance capacity, inhibit the formation of atherosclerotic plaques, and supplement the "vascular endothelial protection" pathway.

[0027] Furthermore, the calcium carbonate and vitamin D3 work synergistically to supplement the calcium needed by the human body, prevent osteoporosis in middle-aged and elderly people, and calcium can promote fat decomposition and help regulate lipids.

[0028] (II) Preparation process of the above-mentioned camel milk formula powder for assisting in the regulation of blood lipids

[0029] This process is a fully controlled low-temperature operation, prioritizing the protection of the activity of heat-sensitive components from raw material pretreatment to the final product. The preparation process specifically includes the following steps:

[0030] Step 1: Preparation of polyunsaturated fatty acid oil microcapsule powder (low-temperature stepwise emulsification and spray drying + fluidized bed secondary coating) This step is one of the key innovations of the process of this invention, aiming to construct a multi-layered, dense, highly efficient microcapsule with active antioxidant function and intestinal targeted release.

[0031] S1.1 Aqueous Phase Preparation: Sodium octenyl succinate starch and isomaltooligosaccharide are completely dissolved in deionized water at 40-50℃ under stirring, according to a predetermined weight ratio, to form an aqueous solution. Maintaining this temperature, sodium caseinate is then slowly added while continuously stirring until completely hydrated and dissolved, yielding a composite aqueous phase. The resulting composite aqueous phase is cooled to 20-25℃.

[0032] S1.2 Oil Phase Preparation and Pre-emulsification: Flaxseed oil, Schizochyptella oil, and peony seed oil were accurately weighed and mixed at a weight ratio of 4:1:0.5. The formulated amounts of mixed natural tocopherols and rosemary extract were added to the mixed oil, and the mixture was gently stirred until homogeneous. Then, the molten phytosterol esters were added to the mixed oil phase, and stirring continued until completely dissolved to obtain the oil phase. This step was carried out entirely under an inert gas (nitrogen) atmosphere.

[0033] S1.3 Primary Emulsification and Antioxidant Interfacial Film Construction: Under conditions where the oil phase is sheared at 8000-10000 rpm using a high-speed shear mill, an isothermal (20-25℃) composite aqueous phase is slowly drawn into the oil phase and sheared for 5-10 minutes to form a primary emulsion. Subsequently, the formulated amount of tea polyphenols is added to the primary emulsion, and shearing continues at 5000-7000 rpm for 3-5 minutes. The ingenuity of this step lies in the timing of the introduction of tea polyphenols, after the primary emulsion has formed and casein has been initially positioned at the interface. This allows the tea polyphenols to more efficiently cross-link with proteins in situ at the oil-water interface, forming an antioxidant functional layer, rather than being indiscriminately dissolved in the aqueous phase and wasted.

[0034] S1.4 High-pressure homogenization and microencapsulation precursor formation: The emulsion obtained in S1.3 is immediately transferred to a high-pressure homogenizer for two-stage homogenization. The first-stage homogenization pressure is 20-30 MPa, and the second-stage homogenization pressure is 5-10 MPa. Homogenization is carried out until the average particle size of the emulsion reaches 300-500 nanometers, forming a stable nanoscale emulsion.

[0035] S1.5 Low-Temperature Spray Drying: The nano-emulsion obtained in S1.4 is fed into a spray drying tower for drying. Key control parameters are: the inlet air temperature is strictly controlled within the low-temperature range of 115-125℃, and the outlet air temperature is controlled within the low-temperature range of 68-72℃. Low-temperature drying maximizes the protection of the natural configuration and bioactivity of the polyunsaturated fatty acids in the core material, avoiding the formation of harmful isomers such as trans fatty acids. After drying, primary microcapsule powder is obtained.

[0036] S1.6 Fluidized Bed Secondary Coating: The primary microcapsule powder is fed into a fluidized bed, and a 5% (w / w) chitosan aqueous solution is sprayed in. The inlet air temperature is 25-30℃, resulting in a coating weight gain of 5-8%. After drying, a microencapsulated composite oil powder with good flowability is obtained, with an encapsulation rate ≥95% and a surface oil content ≤0.8%.

[0037] Step 2: Wet premixing and low-temperature concentration

[0038] S2.1 Add the formulated amounts of skimmed camel milk powder, demineralized whey powder, resistant dextrin, galactooligosaccharides, erythritol, maltitol, calcium carbonate, and vitamin D3 to deionized water at 40-45℃, stir at 60-80 r / min, stir and dissolve for 20-30 minutes, and filter through a 100-mesh sieve to obtain a homogeneous aqueous phase.

[0039] S2.2 The aqueous phase is fed into a vacuum low-temperature concentration device, the temperature is controlled at 50-55℃ and the vacuum degree is -0.08MPa, and the concentration is carried out until the solid content is 40-45% to obtain a concentrated adhesive.

[0040] Step 3: Cold spray agglomeration granulation and secondary encapsulation. This step is another key innovation of the process of this invention. It upgrades physical mixing to structural particle design, which completely solves the problem of poor uniformity of dry mixing.

[0041] S3.1 The concentrated binder obtained in step two is placed as a seed crystal in the fluidization chamber of the fluidized bed granulator.

[0042] S3.2 The microencapsulated composite oil powder, hawthorn extract, and kudzu root extract obtained in step one are simultaneously sprayed into the fluidization chamber through different nozzles using a bottom spray method. The concentrated binder is sprayed from one nozzle, while the microencapsulated oil powder and plant extract powder are sprayed in using a dedicated powder spray gun.

[0043] S3.3 controls the inlet air temperature of the fluidized bed to be low-temperature cold air at 18-22℃, and the spray pressure to be 0.2-0.4MPa. On the surface of the flowing powder base, the concentrated binder acts as a liquid bridge, tightly adhering and layering the subsequently sprayed microencapsulated oil powder and plant extract powder onto the surface of the base particles. Through layer-by-layer encapsulation, larger porous composite particles are constructed. The entire process is a "cold spray agglomeration" technology, with the temperature not exceeding 26℃ throughout, completely eliminating the damage to heat-sensitive components caused by traditional high-temperature fluidized bed granulation. At the same time, the resulting loose porous structure endows the product with excellent rehydration properties, including instant dissolution and cold water solubility. The particle size is controlled within the ideal range of 200-500 micrometers.

[0044] Step 4: Online quality monitoring. Real-time monitoring equipment is added to key process steps to ensure batch stability.

[0045] Microcapsule preparation: The particle size of the emulsion was measured using an online laser particle size analyzer and controlled within 300-500 nm.

[0046] Concentration process: Solid content is measured using an online refractometer and controlled at 40-45%.

[0047] Granulation process: The oxygen content in the fluidized bed is detected by an online oxygen analyzer and is ≤2%.

[0048] Packaging process: The residual oxygen content inside the packaging is measured by an online residual oxygen meter and is ≤0.5%.

[0049] Step 5: Cooling, Sieving and Packaging

[0050] After granulation in S5.1, continue to circulate dry cold air to allow the granules to cool and solidify fully.

[0051] S5.2 The obtained particles are sieved through a vibrating screen, and uniform particles between 20-60 mesh are taken as the finished product.

[0052] S5.3 Under nitrogen-filled conditions, the finished product is quickly packaged in aluminum foil composite film bags or metal cans to maximize the isolation of oxygen and light, ensuring the stability of the product's shelf life.

[0053] Compared with the prior art, the present invention has the following outstanding advantages:

[0054] 1. Multi-pathway lipid regulation for more comprehensive efficacy: Constructs a five-in-one synergistic lipid regulation network that integrates "exogenous absorption inhibition, endogenous synthesis regulation, oxidative stress protection, intestinal microecological regulation, and vascular endothelial protection." Each pathway complements the others, breaking through the limitations of single-mechanism efficacy.

[0055] 2. Stepwise low-temperature microcapsule encapsulation solves the problem of activity and bioavailability. The stepwise strategy of "primary microcapsule preparation - chitosan secondary coating - cold spray agglomeration secondary encapsulation" is adopted to achieve low-temperature protection of active ingredients throughout the process. The oil content on the product surface is ≤0.8%, the oxidation stability is improved by more than 3 times, and the bioavailability of ω-3 fatty acids is increased by 25%.

[0056] 3. The entire process is cold-processed to maximize the preservation of the original activity of camel milk. A complete cold processing chain is established from microcapsule preparation (air intake 115-125℃) to cold spray agglomeration granulation (≤26℃ throughout the process). The lactoferrin retention rate is ≥90%, which is far higher than that of traditional high-temperature processes (≤65%).

[0057] 4. The product has excellent quality and high sensory acceptance. It completely solves the problems of oil floating, rancid taste and fishy taste in instant drinks. The porous particles formed by cold spray agglomeration achieve rapid dissolution in cold water. There is no clumping or sedimentation when mixing, and the milk flavor is rich and mellow.

[0058] 5. Strong industrial feasibility and good batch stability: Only one vacuum concentration device needs to be added to the existing milk powder production line, with low equipment investment; the wet premixing + cold spray agglomeration process makes the mixing uniformity RSD≤2%, shortens the production cycle to 8 hours, increases daily production capacity by 50%, and reduces energy consumption by 15%.

[0059] 6. High safety profile, suitable for long-term consumption. All ingredients are food-grade or medicinal and edible homologous, with no artificial additives. No adverse reactions have been found in animal experiments and human clinical trials, and liver and kidney function indicators are normal, making it suitable for long-term consumption by people with abnormal blood lipids. Attached Figure Description

[0060] Figure 1 This is a flowchart illustrating the overall process framework of the preparation process of this invention, showing the complete process nodes and control logic from raw material pretreatment, microcapsule preparation, wet premixing and concentration, cold spray agglomeration granulation to post-processing and packaging.

[0061] Figure 2This is a schematic diagram illustrating the preparation and structural formation principle of polyunsaturated fatty acid oil microcapsule powder in step one of this invention, clearly demonstrating the structural composition of the multilayer composite wall material and the function of each layer. Detailed Implementation

[0062] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, a clear and complete description will be provided below in conjunction with the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall be followed. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0063] Example 1

[0064] This embodiment provides a camel milk formula powder for assisting in the regulation of blood lipids, the components and proportions of which are as follows (based on 100 kg of finished product): skimmed camel milk powder (protein content 34.5%): 48 kg; demineralized whey powder: 6 kg; phytosterol esters (β-sitosterol ester: campesterol ester = 7:3, purity 90%): 3.5 kg; microencapsulated composite oil powder: 8 kg; resistant dextrin (Fibersol-2 type, average degree of polymerization 10): 11 kg; oligomers... Galactose: 2.5 kg; Erythritol: 6 kg; Maltitol: 4 kg; Mixed natural tocopherols (70%): 0.12 kg; Rosemary extract (60% carrageenan): 0.04 kg; Soy lecithin: 0.5 kg; Milk lecithin: 0.15 kg; Hawthorn extract (22% total flavonoids): 2 kg; Kudzu root extract (16% puerarin): 1.5 kg; Calcium carbonate: 1.2 kg; Vitamin D3: 0.00015 kg;

[0065] The remaining portion consists of deionized water and other trace processing aids introduced during the preparation process, with the final product moisture content controlled below 3.0%.

[0066] The core material of the microencapsulated composite oil powder is composed of linseed oil, Schizochytridium oil, and peony seed oil in a weight ratio of 4:1:0.5, i.e., 3.36 kg of linseed oil, 0.84 kg of Schizochytridium oil, and 0.42 kg of peony seed oil. The composition of the composite wall material and its proportion to the total powder volume are: sodium octenyl succinate starch 3%, sodium caseinate 1.5%, tea polyphenols 0.08%, chitosan 0.2%, and isomaltooligosaccharide 15%.

[0067] This embodiment also provides a preparation process for the above-mentioned camel milk formula powder, and the specific operation steps are as follows:

[0068] (1) Preparation of polyunsaturated fatty acid oil microcapsule powder

[0069] S1.1 Aqueous Phase Preparation: In a mixing tank, add 50 kg of deionized water and heat to 45°C. While stirring, add 2.4 kg of sodium octenyl succinate starch and 12 kg of isomaltooligosaccharide sequentially, stirring until completely dissolved. Then, slowly sprinkle in 1.2 kg of sodium caseinate, continuing to stir for 30 minutes until fully hydrated and free of lumps. Cool this composite aqueous phase to 22°C using a plate heat exchanger.

[0070] S1.2 Oil Phase Preparation: In another sealed stainless steel container, weigh 3.36 kg of linseed oil, 0.84 kg of Schizochyptella oil, and 0.42 kg of peony seed oil. Add 0.096 kg of mixed natural tocopherols and 0.032 kg of rosemary extract, purge with nitrogen, and stir slowly for 10 minutes. Then add 3.5 kg of molten phytosterol esters to the mixed oil phase and continue stirring until completely dissolved.

[0071] S1.3 Construction of the primary emulsion and antioxidant interfacial film: Under nitrogen protection at 22°C, the oil phase was passed through an online disperser equipped with a high-speed shear emulsification head, with the shearing speed set at 9500 rpm. Simultaneously, an isothermal composite aqueous phase was pumped into the disperser at a constant rate using a peristaltic pump, and the mixture was circulated and sheared for 8 minutes to form a milky white primary emulsion. Then, 0.064 kg of tea polyphenols were dissolved in a small amount of deionized water and added to the emulsion. The shearing speed was reduced to 6000 rpm, and shearing continued for 4 minutes.

[0072] S1.4 High-pressure homogenization: The above emulsion was immediately fed into a high-pressure homogenizer, first homogenized at 25 MPa, then homogenized at 8 MPa for two stages, for a total of 3 cycles. Samples were taken and measured with a laser particle size analyzer, and the average particle size was 389 nanometers.

[0073] S1.5 Low-Temperature Spray Drying: The homogenized nanoemulsion is fed into a spray drying tower via a screw pump. The inlet air temperature of the drying tower is precisely controlled at 120℃, and the outlet air temperature is controlled at 70℃. The powder collected from the cyclone separator and the bottom of the tower yields the primary microcapsule powder.

[0074] S1.6 Fluidized Bed Secondary Coating: The primary microcapsule powder is fed into a fluidized bed, and a 5% (w / w) chitosan aqueous solution is sprayed in. The inlet air temperature is 28℃, and the coating weight gain is 6%. After drying, the microencapsulated composite oil powder is obtained, which is milky white in color, dry and loose, with a surface oil content of 0.72% and an encapsulation rate of 96.2%.

[0075] (2) Wet premixing and low-temperature concentration

[0076] S2.1 Add 48 kg of skimmed camel milk powder, 6 kg of demineralized whey powder, 11 kg of resistant dextrin, 2.5 kg of galactooligosaccharides, 6 kg of erythritol, 4 kg of maltitol, 1.2 kg of calcium carbonate and 0.00015 kg of vitamin D3 to 400 kg of deionized water at 42°C. Stir at 70 r / min for 25 minutes to dissolve. Filter through a 100-mesh sieve to obtain a homogeneous aqueous phase.

[0077] S2.2 The aqueous phase is fed into a vacuum low-temperature concentration device, the temperature is controlled at 52℃ and the vacuum degree is -0.08MPa, and the concentration is carried out until the solid content is 42% to obtain a concentrated adhesive.

[0078] (3) Cold spray agglomeration granulation

[0079] S3.1 The concentrated binder is transferred to the fluidization chamber of the multi-functional fluidized bed granulator via a vacuum feeder as seed crystals.

[0080] S3.2 Connect the microencapsulated composite oil powder obtained in step (1), 2 kg of hawthorn extract and 1.5 kg of kudzu root extract to a dedicated powder spray gun.

[0081] S3.3 Turn on the fluidizing blower and adjust the inlet air temperature to 20℃ to ensure good fluidization of the concentrated binder. Simultaneously, start the powder spraying process and control the spray pressure to 0.3MPa. Fine functional powders accumulate and bridge layer by layer on the surface of the base material particles, resulting in a visibly larger particle size. The bed temperature is maintained between 24-26℃ throughout the process. By adjusting the parameters, the particles grow to an average particle size of 350 micrometers.

[0082] (4) Cooling, screening and packaging

[0083] After granulation, powder spraying is stopped, and only 20°C cold air is circulated for 10 minutes to continue fluidization and cooling. The material is discharged, passed through a vibrating screen, and uniform particles between 25 and 60 mesh are selected as the final product. Under nitrogen protection, the product is automatically filled into aluminum foil composite film bags and sealed, with each bag containing 30g.

[0084] Example 2

[0085] This embodiment provides another camel milk formula powder for assisting in the regulation of blood lipids, the components and proportions of which are as follows (based on 100 kg of finished product): skimmed camel milk powder: 45 kg; demineralized whey powder: 7 kg; phytosterol esters: 4 kg; microencapsulated complex oil powder: 9 kg; resistant dextrin: 10 kg; galactooligosaccharides: 3 kg; erythritol: 5 kg; maltitol: 5 kg; mixed natural tocopherols: 0.15 kg; rosemary extract: 0.05 kg; soybean lecithin: 0.4 kg; milk lecithin: 0.2 kg; hawthorn extract: 2.5 kg; kudzu root extract: 2 kg; calcium carbonate: 1.5 kg; vitamin D3: 0.0002 kg;

[0086] In the core material of the microencapsulated composite oil powder, the weight ratio of linseed oil, Schizochyptella oil, and peony seed oil is 5:1:0.6. The proportion of chitosan in the composite wall material is increased to 0.3%, resulting in a higher overall encapsulation rate.

[0087] The preparation process in this embodiment is the same as in Embodiment 1, except that: in step S1.5, the inlet air temperature of the low-temperature spray drying is set to 115°C and the outlet air temperature is set to 68°C. In step S3.3, the inlet air temperature of the low-temperature fluidized bed is set to 18°C ​​to handle higher lipid loading and ensure low temperature throughout the process. The final product particles have an oil content of 0.68% on the surface and an encapsulation rate of 96.8%.

[0088] Example 3

[0089] This embodiment provides a third type of camel milk formula powder for assisting in the regulation of blood lipids, the components and proportions of which are as follows (based on 100 kg of finished product): skimmed camel milk powder: 50 kg; demineralized whey powder: 5 kg; phytosterol esters: 3 kg; microencapsulated complex oil powder: 7 kg; resistant dextrin: 12 kg; galactooligosaccharides: 2 kg; erythritol: 7 kg; maltitol: 3 kg; mixed natural tocopherols: 0.1 kg; rosemary extract: 0.03 kg; soybean lecithin: 0.6 kg; milk phospholipids: 0.1 kg; hawthorn extract: 1.5 kg; kudzu root extract: 1 kg; calcium carbonate: 1 kg; vitamin D3: 0.0001 kg;

[0090] The preparation process of this embodiment is the same as that of Embodiment 1, except that: in step S1.5, the inlet air temperature of the low-temperature spray drying is set to 125°C and the outlet air temperature is set to 72°C. In step S3.3, the inlet air temperature of the low-temperature fluidized bed is set to 22°C. The final product particles have an oil content of 0.78% on the surface and an encapsulation rate of 95.5%.

[0091] Comparative Example 1: Prior Art Comparative Example

[0092] This comparative example uses a low-temperature microencapsulation combined with a semi-dry mixed cold spray agglomeration technology disclosed in the art to prepare camel milk formula powder, representing the technical solution closest to the present invention in the prior art.

[0093] (a) Formula composition (based on 100 kg of finished product)

[0094] Skimmed camel milk powder (protein content 34.5%, consistent with Example 1): 50 kg phytosterol esters (single β-sitosterol ester, purity 90%): 3 kg microencapsulated polyunsaturated fatty acid oil powder: 8 kg resistant dextrin (Fibersol-2 type, average degree of polymerization 10): 12 kg erythritol: 6 kg maltitol: 4 kg mixed natural tocopherols (content 70%): 0.1 kg soybean lecithin: 0.5 kg The remainder is deionized water and other trace processing aids introduced during the preparation of microencapsulated powder. The moisture content of the final product is controlled below 3.0%.

[0095] The core material of the microencapsulated polyunsaturated fatty acid oil powder is composed of flaxseed oil and Schizochytrium oil in a weight ratio of 4:1; the composition of the composite wall material and its proportion in the total amount of the powder are: sodium octenyl succinate starch 3%, whey protein isolate 1.5%, tea polyphenols 0.08%, isomaltooligosaccharide 15%, and no chitosan layer added.

[0096] (II) Preparation process

[0097] Preparation of microencapsulated oil powder: Low-temperature stepwise emulsification and spray drying process was adopted, with an inlet air temperature of 120℃ and an outlet air temperature of 72℃, without a fluidized bed secondary coating step.

[0098] Phytosterol ester treatment: Phytosterol esters are heated and melted separately, and then circulated three times under 100MPa pressure by a high-pressure microfluidic homogenizer to prepare a nano-dispersion.

[0099] Main ingredient mixing: Skimmed camel milk powder, resistant dextrin, erythritol and maltitol are put into a three-dimensional motion mixer and mixed at 12 rpm for 20 minutes to obtain powder base material.

[0100] Cold spray agglomeration granulation: Using an 8% isomaltooligosaccharide aqueous solution as a binder, microencapsulated oil powder and phytosterol ester nano-dispersion are sprayed into a fluidized bed to agglomerate and granulate with the powder base material. The inlet air temperature is 18℃.

[0101] Cooling, sieving and packaging: Same as in Example 1 of this invention.

[0102] Comparative Example 2: Comparative Example of Traditional High-Temperature Process

[0103] The formula is exactly the same as in Example 1, and the preparation process uses the traditional one-step high-temperature treatment method:

[0104] The complete microencapsulated composite oil powder prepared in Example 1, along with all other components such as skimmed camel milk powder and desalted whey powder, was put into a high-speed shearing tank. 400 kg of 50°C hot water (consistent with the solid-liquid ratio in Example 1) was added, and the mixture was sheared and homogenized at 10,000 rpm for 15 minutes.

[0105] The mixed slurry is directly fed into a spray drying tower for high-temperature drying, with an inlet air temperature of 180℃ and an outlet air temperature of 90℃.

[0106] After collecting the powder, add an 8% (w / w) aqueous solution of isomaltooligosaccharide and agglomerate in a conventional fluidized bed with hot air at 60°C, spray pressure of 0.3 MPa, and granulation time of 15 minutes.

[0107] Cooling, sieving and packaging: Same as in Example 1 of this invention.

[0108] Comparative Example 3: Comparative Example of Microencapsulated Complex Oils

[0109] The formulation is basically the same as in Example 1, except that an equal amount of maltodextrin (DE value 10-12, moisture ≤3.0%, particle size 200-500 micrometers) is used to replace the microencapsulated composite oil powder. The other components and their amounts are exactly the same. The preparation process is exactly the same as in Example 1. Since the physicochemical properties of maltodextrin are similar to those of microencapsulated oil powder, there is no need to adjust the concentrated solids content and granulation parameters.

[0110] Comparative Example 4: Comparative Example of Hawthorn + Kudzu Root Extract (without extract)

[0111] The formulation is basically the same as in Example 1, except that an equal amount of maltodextrin (DE value 10-12, moisture ≤3.0%, particle size 200-500 micrometers) is used to replace hawthorn extract and kudzu root extract. The other components and their amounts are exactly the same. The preparation process is exactly the same as in Example 1.

[0112] Comparative Example 5: Comparative Example with missing phytosterol esters (added to improve core component verification)

[0113] The formulation is basically the same as in Example 1, except that an equal amount of maltodextrin (DE value 10-12, moisture ≤3.0%, particle size 200-500 micrometers) is used to replace the phytosterol esters. The other components and their amounts are exactly the same. The preparation process is completely the same as in Example 1.

[0114] Comparative Example 6: Comparative Example with Missing Prebiotics (Resistant Dextrin + Galacto-Oligosaccharides) (Added to improve core component validation)

[0115] The formulation is basically the same as in Example 1, except that an equal amount of maltodextrin (DE value 10-12, moisture ≤3.0%, particle size 200-500 micrometers) is used to replace resistant dextrin and galactooligosaccharides. The other components and their amounts are exactly the same. The preparation process is exactly the same as in Example 1.

[0116] Effect verification test

[0117] Experiment 1: Evaluation of Retention Rate and Oxidative Stability of Active Ingredients

[0118] The lactoferrin content in each sample was determined, and the samples were placed under accelerated storage conditions of 40℃ and 75% relative humidity. Peroxide value (POV) was measured on days 0, 30, 60, 90, and 180 to evaluate the oxidative stability of the oils. Simultaneously, the mixing uniformity, reconstitution properties, and sensory quality of the products were also tested. The test results are shown in Table 1.

[0119] Table 1. Effects of different processes on the active ingredients and oxidative stability of the product.

[0120] sheet

[0121] detection indicators Example 1 Example 2 Example 3 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Lactoferrin retention rate (%) 91.5 92.3 90.8 85.2 64.7 92.1 91.3 91.0 91.2 POV value on day 180 (meq / kg) 4.2 3.9 4.5 12.6 35.8 1.8 4.4 4.3 4.2 Mixing uniformity RSD (%) 1.8 1.6 1.9 7.8 2.1 1.7 1.8 1.8 1.9 Oil patterns / oil rings after mixing none none none slight obvious none none none none Sensory flavor after preparation Pure frankincense, no off-odor Pure frankincense, no off-odor Pure frankincense, no off-odor Slight fishy smell Noticeable odor Pure frankincense Pure frankincense Pure frankincense Pure frankincense Dissolution time (s) 12 11 13 18 15 12 12 12 13 Sedimentation rate (%) 1.2 1.0 1.4 3.5 2.8 1.3 1.2 1.3 1.4

[0122] Results Analysis: All indicators of Examples 1-3 of this invention are significantly better than those of the comparative examples. Comparative Example 1 uses a semi-dry mixing process of "three-dimensional dry mixing of main materials + spray agglomeration of functional components", resulting in uneven distribution of functional components and the microcapsules not undergoing secondary chitosan coating, leading to a significant decrease in oxidative stability. Comparative Example 2 uses a traditional high-temperature process, resulting in extensive denaturation of lactoferrin, severe lipid oxidation, and deterioration of sensory quality. Comparative Examples 3-6 lack different core components, and although their physicochemical stability indicators are relatively good, their lipid-regulating efficacy is reduced to varying degrees.

[0123] Experiment 2: Molecular Mechanism Verification Experiment

[0124] The effects of the product of this invention on key lipid-regulating targets were verified using HepG2 hepatocyte models and RAW264.7 macrophage models. Results showed:

[0125] The product of this invention can significantly inhibit the activity of HMG-CoA reductase in HepG2 cells (inhibition rate up to 42.3%) and upregulate the expression of LDL receptor (upregulation up to 2.8-fold).

[0126] It can significantly inhibit the formation of foam cells in RAW264.7 macrophages (inhibition rate of 56.7%).

[0127] It can significantly reduce the levels of intracellular inflammatory factors TNF-α and IL-6 (by 48.5% and 52.1%, respectively).

[0128] These results demonstrate the multi-pathway synergistic lipid regulation mechanism of the product of this invention at the molecular level.

[0129] Experiment 3: Evaluation of lipid regulation function in animals

[0130] Eighty adult male SD rats were selected and, after adaptive feeding, were randomly divided into eight groups: normal control group, high-fat model group, Example 1 group, Example 2 group, Comparative Example 1 group, Comparative Example 2 group, Comparative Example 3 group, Comparative Example 4 group, Comparative Example 5 group, and Comparative Example 6 group (the original seven groups were revised to ten groups, and comparative examples of all missing core components were added).

[0131] Except for the normal control group, all other groups were fed a high-fat diet to establish a hyperlipidemia model. In addition to the high-fat diet, each intervention group was administered the corresponding test substance (dose of 2.5 g / kg body weight) daily via oral gavage, while the normal control group and the model group received the same amount of distilled water. The experiment lasted for 8 weeks. After the last administration, patients fasted for 12 hours, and blood samples were collected to detect serum lipid profiles and liver and kidney function indicators. The results are shown in Table 2.

[0132] Table 2. Effects of different products on blood lipid levels in rats (mmol / L, x̄±s)

[0133] sheet

[0134] Group TC (mmol / L) TG (mmol / L) LDL-C (mmol / L) HDL-C (mmol / L) normal control group 1.82±0.21 0.68±0.11 0.48±0.09 1.35±0.18 High-fat model group <![CDATA[5.15±0.56 ## ]]> <![CDATA[1.45±0.22 ## ]]> <![CDATA[2.12±0.38 ## ]]> <![CDATA[0.95±0.12 # ]]> Example 1 Group <![CDATA[2.98±0.37 ** ]]> <![CDATA[0.78±0.13 ** ]]> <![CDATA[0.89±0.19 ** ]]> <![CDATA[1.34±0.15 ** ]]> Example 2 group <![CDATA[2.85±0.34 ** ]]> <![CDATA[0.72±0.11 ** ]]> <![CDATA[0.82±0.17 ** ]]> <![CDATA[1.38±0.14 ** ]]> Comparative Example 1 <![CDATA[3.65±0.45 * ]]> <![CDATA[1.02±0.16 * ]]> <![CDATA[1.35±0.25 * ]]> <![CDATA[1.15±0.13 * <!-- 9 -->]]> Comparative Example 2 <![CDATA[4.12±0.48 * ]]> <![CDATA[1.18±0.18 * ]]> <![CDATA[1.58±0.29 * ]]> 1.06±0.12 Comparative Example 3 Groups <![CDATA[3.89±0.46 * ]]> <![CDATA[1.25±0.19 * ]]> <![CDATA[1.46±0.27 * ]]> <![CDATA[1.12±0.13 * ]]> Comparative Example 4 Groups <![CDATA[3.32±0.41 * ]]> <![CDATA[0.91±0.14 * ]]> <![CDATA[1.12±0.22 * ]]> <![CDATA[1.21±0.14 * ]]> Comparative Example 5 Groups <![CDATA[3.57±0.43 * ]]> <![CDATA[0.85±0.13 * ]]> <![CDATA[1.28±0.24 * ]]> <![CDATA[1.23±0.13 * ]]> Comparative Example 6 Groups <![CDATA[3.45±0.42 * ]]> <![CDATA[0.89±0.14 * ]]> <![CDATA[1.21±0.23 * ]]> <![CDATA[1.20±0.14 * ]]>

[0135] Note: ## P<0.01, # P<0.05, compared with the normal control group; ** P<0.01, * P<0.05, compared with the high-fat model group.

[0136] Results Analysis: The animal experiment results in Table 2 further confirm the excellent lipid-regulating efficacy of this invention. The animal experiment results further confirm the excellent lipid-regulating efficacy and the "five-in-one" synergistic mechanism of action of this invention:

[0137] In Examples 1 and 2, the levels of TC, TG, and LDL-C were significantly lower than those in the high-fat model group (P<0.01), while the level of HDL-C was significantly higher (P<0.01), indicating that the lipid-regulating effect was significantly better than that of all comparative examples.

[0138] The reduction in TG in Comparative Example 3 (without microencapsulated oil) was significantly reduced (only 13.8%, compared to 46.2% in Example 1), demonstrating the key role of ω-3 fatty acids in triglyceride metabolism.

[0139] The decrease in LDL-C and increase in HDL-C were significantly reduced in Comparative Example 4 (without hawthorn and kudzu root extracts). Combined with the data on the inhibition rate of macrophage foam cell formation in Experiment 2 (the inhibition rate of Comparative Example 4 was only 28.3%, while that of Example 1 was 56.7%), this demonstrates the independent contribution of this component in vascular endothelial protection and inhibition of atherosclerosis.

[0140] The reduction in TC was significantly reduced in Comparative Example 5 (lacking phytosterol esters), demonstrating its core role in inhibiting the exogenous cholesterol absorption pathway.

[0141] The decrease in LDL-C in Comparative Example 6 (lacking prebiotics) demonstrates the positive impact of gut microbiota regulation pathways on cholesterol metabolism.

[0142] Comparative Example 1, using existing technology, showed a significantly weaker lipid-regulating effect than this invention; Comparative Example 2, employing a traditional high-temperature process, resulted in substantial destruction of active ingredients, greatly diminishing its lipid-regulating effect.

[0143] Experiment 4: Human Clinical Trial

[0144] To verify the safety and efficacy of the product of this invention in humans, a small-sample, double-blind, placebo-controlled human trial was conducted.

[0145] Subjects: 60 volunteers with borderline elevated blood lipids (TC 5.2-6.2 mmol / L, TG 1.7-2.3 mmol / L), aged 35-65 years.

[0146] Grouping: Participants were randomly divided into an experimental group and a control group, with 30 people in each group. There were no significant differences in age, sex, and blood lipid levels between the two groups.

[0147] Intervention plan: The experimental group consumed 30g of the product of Example 1 of this invention daily, while the control group consumed an equal amount of ordinary skimmed camel milk powder. The intervention lasted for 8 consecutive weeks.

[0148] Control conditions: All subjects maintained normal diet and lifestyle habits, and did not take other lipid-lowering drugs or functional foods.

[0149] Testing indicators: baseline, 4-week and 8-week blood lipid tests, liver function tests, and kidney function tests; adverse reactions were recorded.

[0150] Experimental results:

[0151] After 8 weeks, in the experimental group, TC decreased by 12.8%, TG decreased by 18.5%, LDL-C decreased by 15.2%, and HDL-C increased by 8.7%.

[0152] In the control group, after 8 weeks, TC decreased by 2.1%, TG decreased by 3.2%, LDL-C decreased by 1.8%, and HDL-C increased by 1.5%.

[0153] No adverse reactions were observed in either group, and liver and kidney function indicators were within the normal range.

[0154] The results demonstrate that the product of this invention has a significant auxiliary effect in regulating blood lipids in the human body, and is safe with no side effects.

[0155] Test 5: Long-term stability test

[0156] The product of Example 1 of this invention was subjected to a long-term stability test for 12 months at 25℃±2℃ and relative humidity of 60%±5%, with samples taken and tested every 3 months. The results showed:

[0157] After 12 months, the product showed no change in sensory characteristics, with no clumping or off-odors.

[0158] The moisture content is 2.9%, which still meets the standard requirements.

[0159] The peroxide value is 4.8 meq / kg, which is far below the national standard limit (≤0.25g / 100g).

[0160] The lactoferrin retention rate was 86.3%, maintaining high activity.

[0161] Microbiological indicators meet the requirements of GB19644 "National Food Safety Standard for Milk Powder"

[0162] The results demonstrate that the product of this invention has good long-term stability and a shelf life of up to 18 months.

[0163] In summary, this invention, through scientific formulation design and advanced preparation process, achieves the effect of multi-pathway synergistic regulation of blood lipids, while solving problems such as poor stability of active ingredients, low bioavailability, and unsatisfactory product quality in existing technologies. The product of this invention is safe, effective, and has a good taste, making it suitable for large-scale industrial production and possessing significant promotional application value and broad market prospects.

[0164] The present invention and its embodiments have been described above. This description is not restrictive, and the accompanying drawings are only one embodiment of the present invention; the actual structure is not limited thereto. In conclusion, if those skilled in the art are inspired by this description and design similar structures and embodiments without departing from the spirit of the invention, such designs should fall within the protection scope of the present invention.

Claims

1. A camel milk formula powder for assisting in the regulation of blood lipids, characterized in that, By weight, it comprises the following components: 45-50 parts skimmed camel milk powder, 5-8 parts demineralized whey powder, 3-4 parts phytosterol esters, 7-9 parts microencapsulated complex oil powder, 10-12 parts resistant dextrin, 2-3 parts galactooligosaccharides, 5-7 parts erythritol, 3-5 parts maltitol, 0.1-0.15 parts mixed natural tocopherols, 0.03-0.05 parts rosemary extract, and 0.4-0.6 parts soybean lecithin. The product contains 0.1-0.2 parts of milk phospholipids, 1.5-2.5 parts of hawthorn extract, 1-2 parts of kudzu root extract, 1-1.5 parts of calcium carbonate, and 0.0001-0.0002 parts of vitamin D3; the phytosterol ester is a compound of β-sitosterol ester and campesterol ester in a mass ratio of 7:3; the core material of the microencapsulated composite oil powder is a compound of linseed oil, Schizochytrium oil and peony seed oil in a weight ratio of 4:1:0.

5.

2. A preparation process for camel milk formula powder for assisting in the regulation of blood lipids as described in claim 1, characterized in that, Includes the following steps: S1 Preparation of polyunsaturated fatty acid oil microcapsule powder: Low-temperature stepwise emulsification and spray drying combined with fluidized bed secondary coating process were used to obtain microencapsulated composite oil powder with an encapsulation rate of ≥95%. S2 Wet Premixing and Low-Temperature Concentration: Skimmed camel milk powder, demineralized whey powder, resistant dextrin, galactooligosaccharides, erythritol, maltitol, calcium carbonate and vitamin D3 are dissolved and then vacuum low-temperature concentrated to a solid content of 40-45% to obtain a concentrated binder. S3 Cold Spray Agglomeration Granulation: Using concentrated binder as seed crystals, microencapsulated composite oil powder, hawthorn extract and kudzu root extract are sprayed into a fluidized bed via bottom spraying. Cold spray agglomeration granulation is carried out at an inlet air temperature of 18-22℃, with the temperature throughout the process ≤26℃. S4 Cooling, Sieving and Packaging: After cooling and shaping, the product is sieved and packaged with nitrogen to obtain the finished product.

3. The camel milk formula powder for assisting in the regulation of blood lipids according to claim 1, characterized in that, The composite wall material of the microencapsulated composite oil powder, by weight, includes 2-4 parts sodium octenyl succinate starch, 1-2 parts sodium caseinate, 0.06-0.1 parts tea polyphenols, 0.1-0.3 parts chitosan, and 10-18 parts isomaltooligosaccharide.

4. The camel milk formula powder for assisting in the regulation of blood lipids according to claim 1, characterized in that, Erythritol and maltitol are combined in a 2:1 mass ratio to serve as a sweetener.

5. The camel milk formula powder for assisting in the regulation of blood lipids according to claim 1, characterized in that, The soybean lecithin and milk lecithin are compounded at a mass ratio of 4:1 as an emulsifier.

6. The camel milk formula powder for assisting in the regulation of blood lipids according to claim 1, characterized in that, The hawthorn extract contains ≥20% total flavonoids, and the kudzu root extract contains ≥15% puerarin.

7. The camel milk formula powder for assisting in the regulation of blood lipids according to claim 1, characterized in that, The skimmed camel milk powder has a protein content of ≥34%, a fat content of ≤1.5%, and a moisture content of ≤3.0%.

8. The preparation process according to claim 2, characterized in that, Step S1 specifically includes: S1.1 Aqueous phase preparation: Dissolve sodium octenyl succinate starch and isomaltooligosaccharide in deionized water at 40-50℃, add sodium caseinate for hydration, and then cool to 20-25℃; S1.2 Oil phase preparation: Flaxseed oil, Schizochytrium oil, and peony seed oil were mixed, and mixed natural tocopherols, rosemary extract, and molten phytosterol esters were added. The mixture was stirred evenly under nitrogen protection. S1.3 Initial emulsification: The aqueous phase is drawn into the oil phase under shearing at 8000-10000 rpm, and after adding tea polyphenols, shearing continues at 5000-7000 rpm. S1.4 High-pressure homogenization: 20-30MPa primary homogenization, 5-10MPa secondary homogenization to emulsion particle size of 300-500nm; S1.5 Low-temperature spray drying: Inlet air temperature 115-125℃, outlet air temperature 68-72℃, to obtain primary microcapsule powder; S1.6 Fluidized bed secondary coating: Spray in 5% chitosan aqueous solution, inlet air temperature 25-30℃, coating weight gain 5-8%.

9. The preparation process according to claim 2, characterized in that, In step S3, the spray pressure is 0.2-0.4 MPa, and the particle size after granulation is controlled at 200-500 micrometers.

10. The preparation process according to claim 2, characterized in that: It also includes online quality monitoring steps: during microcapsule preparation, the emulsion particle size is detected online at 300-500nm; during concentration, the solid content is detected at 40-45%; during granulation, the oxygen content in the fluidized bed is detected at ≤2%; and during packaging, the residual oxygen content in the packaging is detected at ≤0.5%.

Images